Lundbeck acquires phase I-ready candidate from South Korean firm

Lundbeck has gained exclusive rights to biotherapy candidate APB-A1 from Aprilbio. The deal may cost up to USD 448m, and Lundbeck sees potential for the drug in several neurological indications.

Photo: Jens Dresling

Danish pharmaceutical giant Lundbeck has acquired exclusive rights to a biotherapy candidate for treating neurological diseases from Aprilbio, in a deal that may cost up to USD 448m.

This will hopefully liven up the company's pipeline, which has been sluggish of late.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs